In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
As of close of business last night, CRISPR Therapeutics AG’s stock clocked out at $36.99, down -5.76% from its previous closing price of $39.25. In other words, the price has decreased by -$5.76 from its previous closing price. On the day, 2.0 million shares were traded.
Ratios:
To gain a deeper understanding of CRSP’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 15.64 and its Current Ratio is at 15.64. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.11.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Evercore ISI on February 14, 2025, Upgraded its rating to Outperform and sets its target price to $99 from $60 previously.
On February 12, 2025, TD Cowen Upgraded its rating to Hold which previously was Sell but kept the price unchanged to $35.
On February 03, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $65.H.C. Wainwright initiated its Buy rating on February 03, 2025, with a $65 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 21 ’25 when Kulkarni Samarth sold 10,031 shares for $41.23 per share. The transaction valued at 413,578 led to the insider holds 195,085 shares of the business.
Bruno Julianne sold 1,714 shares of CRSP for $70,668 on Mar 21 ’25. The Chief Operating Officer now owns 10,544 shares after completing the transaction at $41.23 per share. On Mar 21 ’25, another insider, Prasad Raju, who serves as the Chief Financial Officer of the company, sold 2,197 shares for $41.23 each. As a result, the insider received 90,582 and left with 16,767 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 84.80 while its Price-to-Book (P/B) ratio in mrq is 1.75.
Stock Price History:
Over the past 52 weeks, CRSP has reached a high of $67.88, while it has fallen to a 52-week low of $30.04. The 50-Day Moving Average of the stock is -1.92%, while the 200-Day Moving Average is calculated to be -15.78%.
Shares Statistics:
A total of 86.36M shares are outstanding, with a floating share count of 82.80M. Insiders hold about 4.13% of the company’s shares, while institutions hold 69.15% stake in the company.
Earnings Estimates
The dynamic stock of CRISPR Therapeutics AG (CRSP) is currently being evaluated by a team of 18.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$1.33, with high estimates of -$1.04 and low estimates of -$1.68.
Analysts are recommending an EPS of between -$3.81 and -$6.71 for the fiscal current year, implying an average EPS of -$5.43. EPS for the following year is -$4.4, with 24.0 analysts recommending between $2.55 and -$6.82.
